Follow-Up of Patients With SIHD e427 6.2.1. Focused Follow-Up Visit: Frequency e428 6.2.2. Focused Follow-Up Visit: Interval History and Coexisting Conditions e428 6.2.3. Focused Follow-Up Visit: Physical Examination e429 6.2.4. Focused Follow-Up Visit: Resting 12-Lead ECG e429 6.2.5. Focused Follow-Up Visit: Laboratory Examination e429 6.3. Noninvasive Testing in Known SIHD e429 6.3.1. Follow-Up Noninvasive Testing in Patients With Known SIHD: New, Recurrent, or Worsening Symptoms Not Consistent With Unstable Angina: Recommendations e429 6.3.1.1. Patients Able to Exercise e429 6.3.1.2. Patients Unable to Exercise e430 6.3.1.3. Irrespective of Ability to Exercise e430 6.3.2. Noninvasive Testing in Known SIHD Asymptomatic (or Stable Symptoms): Recommendations e431 6.3.3. Factors Influencing the Use of Follow-Up Testing e432 6.3.4. Patient Risk and Testing e432 6.3.5. Stability of Results After Normal Stress Testing in Patients With Known SIHD e433 6.3.6. Utility of Repeat Stress Testing in Patients With Known CAD e433 6.3.7. Future Developments e434 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) e464 Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) e467 Appendix 3. Abbreviations List e470 Appendix 4. Nomogram for Estimating Year CAD Event-Free Survival e471 Preamble The medical profession should play a central role in evalu- ating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist physicians in selecting the best management strategy for an individual patient. 